Seppe, in memoriam, lived with PKAN Syndrome (Pantothenate Kinase-Associated Neurodegeneration)

Impatient for Patients

We’re racing to develop treatments for genetic conditions.

Moving at the speed of patient need.

Our hub-and-spoke model is designed to unlock speed, precision, and scalability. Teams operate autonomously as individual ‘spokes’, focused on a specific condition or drug candidate, while our central 'hub’ provides clinical, regulatory, and commercial capabilities & expertise.

We partner with leading academic institutions, furthering academic and late-stage clinical research, aiming to bring the most promising advancements to light.

2000+
2000+ patients are enrolled in our clinical trials globally.
100%
100% of our pipeline contains first-in-class or best-in-class therapies.
48
48 unique disease indications have been targeted in our programs over the past 10 years.
6
6 Phase 3 trials have been conducted over the past 10 years.

The Bridge Way

Our decentralized model rethinks what's possible for patients with genetic conditions. We call this The Bridge Way, and it's how we accelerate discovery, reduce the risk of failure, and deliver results.

A FOUNDATION FOR TRANSFORMATION

A focus on genetic conditions provides the clarity we need to target diseases at their source. And we make sure that existing early-stage research doesn’t sit on the shelf by partnering with academic institutions to give promising work a future.

AN INNOVATIVE, PROVEN MODEL

Our model puts agility first, letting us pursue many paths and pivot with purpose. By connecting focused affiliate teams through shared resources and expertise, we move faster and smarter for patients. 

A FOCUS ON GREATER IMPACT

Every step we take is designed to maximize impact for people living with genetic conditions. Our model allows us to advance many therapies at once and quickly adapt to focus on the most promising opportunities to provide first-in-class treatments.

We don’t hope for change. We drive it.

If you’re motivated by the chance to develop transformative treatments for people living with genetic conditions and change the industry in the process, we want to hear from you.

Explore careers

The Bridge Ecosystem

  • BridgeBio Oncology Therapeutics (BBOT)

    Developing bioavailable small molecule inhibitors for people with cancers driven by RAS and PI3Kα.

  • GondolaBio

    Developing transformational therapeutics for people with genetic diseases, with a focus on early-stage research and development.

Scientific Presentations

Explore all

Conditions

Learn more about the conditions we’re focused on.

Learn more

Patient Stories

Meet the people that motivate us.

Explore all